Measles Infection Review Articles
Measles is a highly contagious
infectious disease caused by
measles virus. Symptoms usually develop 10–12 days after exposure to an infected person and last 7–10 days. Initial symptoms typically include fever, often greater than 40 °C (104 °F), cough, runny nose, and inflamed eyes. Small white spots known as Koplik's spots may form inside the mouth two or three days after the start of symptoms.A red, flat rash which usually starts on the face and then spreads to the rest of the body typically begins three to five days after the start of symptoms. Common complications include diarrhea (in 8% of cases), middle ear
infection (7%), and pneumonia (6%). These occur in part due to measles-induced immunosuppression. Less commonly seizures, blindness, or
inflammation of the
brain may occur.Other names include morbilli, rubeola, red measles, and English measles.Both rubella, also known as German measles, and roseola are different diseases caused by unrelated viruses.
Measles is an airborne disease which spreads easily from one person to the next through the coughs and sneezes of infected people. It may also be spread through direct contact with mouth or nasal secretions. It is extremely contagious–nine out of ten people who are not immune and share living space with an infected person will be infected. People are infectious to others from four days before to four days after the start of the rash. Most people do not get the disease more than once.Testing for the
measles virus in suspected cases is important for public
health efforts
High Impact List of Articles
-
Award Content - Spine 2020 on World Congress on Spine and Spinal Disorders, April 13-14, 2020 | Dubai, UAE
Wagih El Masri
Editorial: Journal of Experimental Stroke & Translational Medicine
-
Award Content - Spine 2020 on World Congress on Spine and Spinal Disorders, April 13-14, 2020 | Dubai, UAE
Wagih El Masri
Editorial: Journal of Experimental Stroke & Translational Medicine
-
Clinical risk factors associated with functional outcomes of thrombolytic therapy in stroke and non-stroke units
Meagan Reynolds, Brice Blum, Leanne Brechtel, Jordan Gainey and Thomas I Nathaniel*
Research Article: Journal of Experimental Stroke & Translational Medicine
-
Clinical risk factors associated with functional outcomes of thrombolytic therapy in stroke and non-stroke units
Meagan Reynolds, Brice Blum, Leanne Brechtel, Jordan Gainey and Thomas I Nathaniel*
Research Article: Journal of Experimental Stroke & Translational Medicine
-
Fundamentals of clinical trial design
Scott R. Evans
Review Article: Journal of Experimental Stroke & Translational Medicine
-
Fundamentals of clinical trial design
Scott R. Evans
Review Article: Journal of Experimental Stroke & Translational Medicine
-
Clinical trial structures
Scott R. Evans
Review Article: Journal of Experimental Stroke & Translational Medicine
-
Clinical trial structures
Scott R. Evans
Review Article: Journal of Experimental Stroke & Translational Medicine
-
The Continued Promise of Neuroprotection for Acute Stroke Treatment
Shimin Liu and Steven R Levine
Review Article: Journal of Experimental Stroke & Translational Medicine
-
The Continued Promise of Neuroprotection for Acute Stroke Treatment
Shimin Liu and Steven R Levine
Review Article: Journal of Experimental Stroke & Translational Medicine
Relevant Topics in Clinical